3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
11
Lung Neoplasms
5
Lymphoma, Large-Cell, Anaplastic
2
Brain Neoplasms
2
Sexual Dysfunction, Physiological
1
Neuroma, Acoustic
1
Neurofibromatosis 2
1
Neoplasm Metastasis
1
NSCLC
1
Meningioma
1
Granuloma, Plasma Cell
1
Gastrointestinal Neoplasms
1
Eunuchism
1
Erectile Dysfunction
1
Ependymoma
1
Disease Progression
1
Carcinoma, Pancreatic Ductal
1
Carcinoma
1
Breast Neoplasms
1
Interventions
Temozolomide
16
Magnetic Resonance Spectroscopy
10
Etoposide
9
Cyclophosphamide
8
Radiotherapy
7
Carboplatin
7
Bevacizumab
7
Filgrastim
6
Thiotepa
5
Radiation
4
Biopsy
4
Azacitidine
4
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
4
sargramostim
3
etoposide phosphate
3
Surveys and Questionnaires
3
Peripheral Blood Stem Cell Transplantation
3
Nivolumab
3
Methotrexate
3
Irinotecan
3
Gadolinium DTPA
3
Cisplatin
3
Automobiles
3
lutetium Lu 177 dotatate
2
fluorodopa F 18
2
alovudine
2
aldesleukin
2
Yoga
2
Topotecan
2
Thalidomide
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Ependymoma
×
brigatinib
×
Clear all
NCT04374305
2026-05-06
INTUITT-NF2
Massachusetts General Hospital
Phase 2
Recruiting
109 enrolled